H.R. 9599: To strengthen the 340B drug discount program.
H.R. 9599 status: Referred.
What this bill does
Overall score
Bill summary
AI SummaryThe bill fundamentally restructures the 340B drug discount program, affecting billions of dollars in drug spending, operational requirements for thousands of hospitals, and the compliance landscape for manufacturers and pharmacy benefit managers.
Key analysis
Impact analysis
Environment
Benefits
- no identified direct impact
Risks
- no identified direct impact
Economy
Benefits
- reduces fraud via mandatory independent audits
- standardizes oversight to prevent duplicate discounts
Risks
- significant administrative compliance costs for hospitals
- potential disruption to current 340B contract pharmacy workflows
Society
Benefits
- strengthens patient affordability and charity care requirements
- prohibits aggressive medical debt collection tactics
Risks
- potential reduction in site eligibility could impact care access for specific populations
How trustworthy & consequential it is
Confidence
highhigh
Information is complete and verified.
Analysis status
Full bill text (Congress.gov)
Source used for this bill's analysis.
increased regulatory reporting and audit requirements may strain resources of smaller, rural, or underfunded safety-net hospitals
long-term impact of new user fee structure on safety-net budgets is unknown
Where it stands
Introduced
CompleteCommittee
CurrentReferred
Floor
UpcomingEnacted
UpcomingHow it affects your district
Set your location
Add your district to see how this bill may affect your community and who to contact.
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.